Edwards Lifesciences Corporation – NYSE:EW
Edwards Lifesciences stock price today
$80.24
+4.58
+6.07%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
Edwards Lifesciences stock price monthly change
-16.86%
month
Edwards Lifesciences stock price quarterly change
-16.86%
quarter
Edwards Lifesciences stock price yearly change
-0.73%
year
Edwards Lifesciences key metrics
Market Cap | 43.35B |
Enterprise value | 50.30B |
P/E | 33.55 |
EV/Sales | 9.34 |
EV/EBITDA | 26.15 |
Price/Sales | 9.36 |
Price/Book | 8.67 |
PEG ratio | 16.17 |
EPS | 2.33 |
Revenue | 6.14B |
EBITDA | 1.88B |
Income | 1.41B |
Revenue Q/Q | 9.49% |
Revenue Y/Y | 11.68% |
Profit margin | 28.28% |
Oper. margin | 32.49% |
Gross margin | 79.93% |
EBIT margin | 32.49% |
EBITDA margin | 30.71% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEdwards Lifesciences stock price history
Edwards Lifesciences stock forecast
Edwards Lifesciences financial statements
Average Price Target
$74.15
Potential downside: -7.58%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1.53B | 307.1M | 20.07% |
|---|---|---|---|
| Sep 2023 | 1.48B | 384.9M | 25.99% |
| Dec 2023 | 1.53B | 369.9M | 24.11% |
| Mar 2024 | 1.59B | 351.9M | 22.02% |
| Jun 2023 | 9004000000 | 2.55B | 28.4% |
|---|---|---|---|
| Sep 2023 | 9370800000 | 2.64B | 28.21% |
| Dec 2023 | 9363200000 | 2.64B | 28.24% |
| Mar 2024 | 9736300000 | 2.54B | 26.19% |
| Jun 2023 | 33.6M | 70.2M | 52.1M |
|---|---|---|---|
| Sep 2023 | 411.5M | 89M | -143.3M |
| Dec 2023 | 136.6M | 14.1M | -413.2M |
| Mar 2024 | -53.5M | 63.1M | 61.7M |
Edwards Lifesciences alternative data
| Sep 2023 | 17,300 |
|---|---|
| Oct 2023 | 17,300 |
| Nov 2023 | 17,300 |
| Dec 2023 | 17,300 |
| Jan 2024 | 17,300 |
| Feb 2024 | 17,300 |
| Mar 2024 | 19,800 |
| Apr 2024 | 19,800 |
| May 2024 | 19,800 |
| Jun 2024 | 19,800 |
| Jul 2024 | 19,800 |
Edwards Lifesciences other data
79.26%
-2.16%
of EW is owned by hedge funds
1.26K
-20
500.29M
-14.02M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 0 | 14242 |
| Jun 2024 | 0 | 11160 |
| Jul 2024 | 0 | 5500 |
| Aug 2024 | 0 | 6250 |
| Sep 2024 | 0 | 5000 |
| Oct 2024 | 0 | 5000 |
| Nov 2024 | 0 | 30000 |
| Dec 2024 | 0 | 21083 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | LIPPIS DANIEL J. officer: CVP, JAPAC | Common Stock | 2,500 | $45.28 | $113,193 | ||
Sale | LIPPIS DANIEL J. officer: CVP, JAPAC | Common Stock | 2,500 | $74.08 | $185,195 | ||
Option | LIPPIS DANIEL J. officer: CVP, JAPAC | Employee Stock Option (Right to Acquire) | 2,500 | $45.28 | $113,193 | ||
Option | ULLEM SCOTT B. officer: CVP, Chi.. | Employee Stock Option (Right to Acquire) | 11,250 | $45.28 | $509,366 | ||
Option | ULLEM SCOTT B. officer: CVP, Chi.. | Common Stock | 11,250 | $45.28 | $509,366 | ||
Sale | ULLEM SCOTT B. officer: CVP, Chi.. | Common Stock | 11,250 | $71.68 | $806,411 | ||
Option | BOBO DONALD E JR officer: CVP,Stra.. | Common Stock | 5,000 | $45.28 | $226,385 | ||
Sale | BOBO DONALD E JR officer: CVP,Stra.. | Common Stock | 5,000 | $71.75 | $358,750 | ||
Option | BOBO DONALD E JR officer: CVP,Stra.. | Employee Stock Option (Right to Acquire) | 5,000 | $45.28 | $226,385 | ||
Sale | CHOPRA DAVEEN officer: CVP, TMTT | Common Stock | 1,750 | $73.27 | $128,223 |
| Patent |
|---|
Grant Filling date: 11 Feb 2020 Issue date: 20 Sep 2022 |
Grant Utility: Heart reshaping system Filling date: 7 Feb 2020 Issue date: 20 Sep 2022 |
Grant Filling date: 23 Dec 2019 Issue date: 20 Sep 2022 |
Grant Filling date: 19 Jun 2020 Issue date: 13 Sep 2022 |
Application Filling date: 27 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 26 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 25 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 23 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 23 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 20 May 2022 Issue date: 8 Sep 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 25 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 26 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 26 Jul 2023 | Q2 2023 Earnings Call Transcript |
Edwards Lifesciences: With A Heart Beating Strong And Steady
Wedgewood Partners: Q4 And 2024 Top Performers And Detractors
4 Strong Stock Charts For 2025 (Technical Analysis)
Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Edwards Lifesciences Q3: Clinical Trial Updates Impress
Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Becton, Dickinson and Company: This Serial-Acquirer Is A Buy
Edwards Lifesciences: Solid, Not Spectacular
Ranking The Diversified Healthcare Giants
-
What's the price of Edwards Lifesciences stock today?
One share of Edwards Lifesciences stock can currently be purchased for approximately $80.24.
-
When is Edwards Lifesciences's next earnings date?
Unfortunately, Edwards Lifesciences's (EW) next earnings date is currently unknown.
-
Does Edwards Lifesciences pay dividends?
No, Edwards Lifesciences does not pay dividends.
-
How much money does Edwards Lifesciences make?
Edwards Lifesciences has a market capitalization of 43.35B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 11.56% to 6B US dollars.
-
What is Edwards Lifesciences's stock symbol?
Edwards Lifesciences Corporation is traded on the NYSE under the ticker symbol "EW".
-
What is Edwards Lifesciences's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Edwards Lifesciences?
Shares of Edwards Lifesciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Edwards Lifesciences's key executives?
Edwards Lifesciences's management team includes the following people:
- Mr. Michael A. Mussallem Chairman & Chief Executive Officer(age: 72, pay: $2,090,000)
- Mr. Jean-Luc Lemercier Corporation Vice President of Europe, Middle East, Africa, Canada & Latin America(age: 68, pay: $1,130,000)
- Mr. Scott B. Ullem Corporation Vice President & Chief Financial Officer(age: 58, pay: $1,060,000)
- Mr. Larry L. Wood Corporation Vice President of Transcatheter Aortic Valve Replacement(age: 59, pay: $1,010,000)
- Mr. Donald E. Bobo Jr. Corporation Vice President of Strategy & Corporation Devel.(age: 63, pay: $970,810)
-
How many employees does Edwards Lifesciences have?
As Jul 2024, Edwards Lifesciences employs 19,800 workers.
-
When Edwards Lifesciences went public?
Edwards Lifesciences Corporation is publicly traded company for more then 25 years since IPO on 27 Mar 2000.
-
What is Edwards Lifesciences's official website?
The official website for Edwards Lifesciences is edwards.com.
-
Where are Edwards Lifesciences's headquarters?
Edwards Lifesciences is headquartered at One Edwards Way, Irvine, CA.
-
How can i contact Edwards Lifesciences?
Edwards Lifesciences's mailing address is One Edwards Way, Irvine, CA and company can be reached via phone at +94 92502500.
-
What is Edwards Lifesciences stock forecast & price target?
Based on 11 Wall Street analysts` predicted price targets for Edwards Lifesciences in the last 12 months, the avarage price target is $74.15. The average price target represents a -7.58% change from the last price of $80.24.
Edwards Lifesciences company profile:
Edwards Lifesciences Corporation
edwards.comExchange:
NYSE
Full time employees:
19,800
Industry:
Medical - Devices
Sector:
Healthcare
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
One Edwards Way
Irvine, CA 92614
Irvine, CA 92614
CIK: 0001099800
ISIN: US28176E1082
CUSIP: 28176E108
